
HROW Stock Forecast & Price Target
HROW Analyst Ratings
Bulls say
Harrow Inc. is strategically positioned to capitalize on the growing market for biosimilars, which has seen a penetration rate exceeding 40% in key therapeutic categories since 2015, aligning with healthcare cost reduction efforts. The company is projected to experience significant revenue growth, with expectations for quarterly revenue run rates to exceed $250 million by the fourth quarter of 2027, representing an increase of nearly four times compared to actual figures from the second quarter of 2025. Continued prescription growth momentum, as evidenced by recent data from IQVIA and Symphony Health, further supports the positive outlook for Harrow's product sales moving forward.
Bears say
Harrow Inc faces significant risks related to its product development pipeline, particularly concerning the ability of its spinouts to generate favorable clinical data and achieve regulatory approval, which could adversely impact the company's overall valuation. Furthermore, the potential for slow adoption rates of Harrow's existing and new assets poses an additional threat to the firm's financial performance, as any delays in market acceptance could lead to diminished revenue projections. Lastly, the possibility of unfavorable regulatory changes could further disrupt Harrow's operations and negatively influence its financial stability.
This aggregate rating is based on analysts' research of Harrow Health Inc and is not a guaranteed prediction by Public.com or investment advice.
HROW Analyst Forecast & Price Prediction
Start investing in HROW
Order type
Buy in
Order amount
Est. shares
0 shares